Southern Co (SO) Stock News

Sony stock gained 1.83% to $23.95, outperforming the broader market decline. The company's upcoming earnings are expected to show an 8.57% EPS increase year-over-year, though revenue is projected to decline 5.46%. For the full year, Sony is expected to deliver 27.19% earnings growth despite a 1.98% revenue decline. Sony currently holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 16.19, trading at a premium to its industry average.

MINISO Group (MNSO) gained 1.45% to $9.07, outperforming the broader market decline. The stock has declined 3.14% over the past month. Analysts expect upcoming earnings of $0.39 per share (up 11.43% YoY) and revenue of $1.01 billion (up 24.46% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 7.27, trading at a discount to its industry average of 13.88.

NOVONIX Limited announced it has achieved ISO 9001:2015 certification for its quality management systems, marking a significant milestone as the company scales its Riverside facility in Chattanooga, Tennessee for commercial production of synthetic graphite anode materials. The certification demonstrates NOVONIX's capability to consistently manufacture high-performance battery materials at commercial scale and supports customer qualification requirements for major battery cell manufacturers.

Southern Co. (SO) closed at $85.44, up 1.97%, outperforming the S&P 500's 0.58% gain. The company is expected to report earnings on November 5, 2026, with projected EPS of $1.65 (up 3.13% YoY) and revenue of $8.34 billion (up 6.56% YoY). SO currently holds a Zacks Rank #3 (Hold) with a Forward P/E of 18.25, trading at a premium to its industry average of 16.68.

SoundHound AI (SOUN) is trending among investors despite a -12.8% monthly decline. The company shows strong revenue growth (+47.7% YoY for current quarter) and has beaten consensus estimates, earning a Zacks Rank #2 (Buy) rating. However, the stock trades at a premium valuation (F grade) and is expected to post losses in the current fiscal year before returning to profitability next year.

MINISO Group Holding Limited (MNSO) is trending among investors. The stock has declined 7% over the past month while the S&P 500 gained 0.8%. Despite strong revenue growth projections of 25.4% for the current fiscal year and 15% for next year, earnings estimates remain flat with a Zacks Rank #3 (Hold) rating. The company trades at a valuation discount to peers with a Grade A Value Score.

NOMAD Power Solutions announced that its Special Meeting of Stockholders was adjourned on October 2, 2026, without conducting business. The meeting will reconvene on October 30, 2026, to allow additional time to finalize the Nasdaq listing filing following the merger with NOMAD Transportable Power Systems. The Board continues to recommend stockholders vote 'FOR' the proposals.

The 2026 BayAreaCISO ORBIE Awards recognized six leading CISOs for exceptional security leadership and business impact. Winners included executives from Monolithic Power Systems, Synopsys Inc., TriNet, Dayforce, SLAC National Accelerator Laboratory, and ABC Fitness. The awards ceremony, held at the Santa Clara Marriott with over 180 attendees, honored CISOs across six categories based on leadership effectiveness, business protection, and industry engagement.

Vishay Intertechnology introduced four new 650 V superjunction MOSFET power modules in the industry-standard SOT-227 package, featuring optimized conduction and switching losses for industrial applications. The devices are available in single-switch and low side chopper configurations with current ratings from 50 A to 150 A, offering drop-in replacement compatibility to eliminate PCB redesign costs.

SOLIC announced that Jeffrey Lewis, a veteran investment banker with over 30 years of experience in strategic and financial advisory, has joined the firm as Senior Managing Director. Lewis previously held senior positions at Houlihan Lokey and PricewaterhouseCoopers, bringing expertise in M&A, restructuring, and capital structure solutions across multiple industries.

Eupraxia Pharmaceuticals announced positive 52-week data from its Phase 1b/2a RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE). The highest dose cohorts demonstrated durable symptom responses with 64% of patients maintaining clinical remission at 52 weeks, meaningful histologic improvements, and a favorable safety profile with no serious adverse events or oropharyngeal candidiasis reported. The company plans to report Phase 2b interim data in December 2026.

Southern Co. (SO) closed at $83.45, up 1.34% in the latest session, outperforming the broader market. The utility company is expected to report earnings on November 5, 2026, with analysts projecting $1.65 EPS (up 3.13% YoY) and $8.34B in revenue (up 6.56% YoY). The stock carries a Zacks Rank #3 (Hold) with a Forward P/E of 17.94, trading at a premium to its industry average.

HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.

SoundHound AI (SOUN) closed at $6.01, down 1.8%, underperforming the S&P 500's 0.76% decline. The stock has fallen 13.19% over the past month while the broader market gained. Despite revenue growth projections of 48.47% for the upcoming quarter and 41.02% for the full year, the company is expected to report negative earnings of -$0.06 per share (down 100% YoY) and -$0.18 for the full year. SOUN currently holds a Zacks Rank #2 (Buy) rating.

SoFi Technologies (SOFI) rose 1.12% to $17.16 in the latest session. The stock has declined 6.96% over the past month, underperforming the S&P 500's 1.27% gain. Upcoming earnings are projected at $0.17 per share (54.55% YoY growth) with revenue expected at $1.24 billion (31.08% increase). The company holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 28.15, trading at a premium to its industry average of 11.69.

CalendarBridge announced the completion of its SOC 2 Type II examination, providing independent security validation for its cross-organization calendar synchronization platform. The examination, conducted by Securance Pro Assurance PLLC from June to September 2026, assessed controls supporting Security, Confidentiality, and Availability. The platform serves over 100,000 users and integrates with Google Calendar, Microsoft 365, Apple iCloud, and CalDAV-compatible services while maintaining account and privacy boundaries.

HMG Strategy is hosting its 17th Annual Detroit C-Level Technology Leadership Summit on September 24 at Orchard Lake Country Club, bringing together CIOs, CISOs and senior technology executives from leading organizations across Detroit, Southeast Michigan and Ontario, Canada. The summit will focus on critical topics including AI governance, Agentic AI, cybersecurity resilience, enterprise transformation and the evolving role of the "CEO of Technology." Attendance is complimentary for qualified senior technology executives.

Zacks presents its Focus List, a curated portfolio of 50 stocks selected based on positive earnings estimate revisions. The list has historically outperformed the S&P 500, with cumulative returns of 2,519.23% since February 1996 compared to the S&P's 854.95%. The methodology relies on the Zacks Rank system, which evaluates stocks based on earnings consensus among analysts. Solventum (SOLV), a healthcare company spun off from 3M, is highlighted as a recent addition that has gained 29.89% since April 2024.

While major market indices declined on September 14, 2026, SoFi Technologies (SOFI) gained 1.91% to close at $17.65. The stock outperformed the broader market despite the S&P 500 falling 0.48%. Analysts expect strong earnings growth with EPS projected at $0.17 (up 54.55% YoY) and revenue of $1.24 billion (up 31.08% YoY). However, SOFI trades at a premium valuation with a Forward P/E of 28.73 versus its industry average of 11.74, and currently holds a Zacks Rank of #3 (Hold).

SoundHound AI (SOUN) has an average brokerage recommendation of 1.75 (Strong Buy/Buy) with five of eight firms rating it Strong Buy. However, the article cautions that brokerage recommendations often have positive bias due to vested interests. The company's Zacks Rank #2 (Buy) rating is based on a 21.8% increase in consensus earnings estimates over the past month, suggesting analyst optimism about near-term price appreciation.

Bristol Myers Squibb's SOTYKTU (deucravacitinib), a first-in-class TYK2 inhibitor, has received FDA approval for psoriatic arthritis in March 2026, expanding its commercial potential beyond plaque psoriasis. The drug demonstrates sustained efficacy with PASI 75 response rates of 67%-73% through five years and over 5,000 patient-years of safety data. Market analysis forecasts SOTYKTU sales across seven major markets through 2034, with growth driven by oral convenience, selective mechanism of action, and potential expansion into additional immune-mediated inflammatory disease indications including lupus, Sjogren's syndrome, and Crohn's disease.

Comstock Resources (CRK) has announced a $1.65 billion strategic partnership with Azerbaijan's SOCAR and a $450 million drilling joint venture with Jerry Jones. The deals will reduce pro forma net debt from $3.1 billion to $1.5 billion, provide LNG marketing capabilities, and fund drilling of 27 wells in the Haynesville while CRK retains operational control. The SOCAR transaction is expected to close by year-end 2026.

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.

Solventum Corporation (SOLV), a healthcare company spun off from 3M, has been added to the Zacks Focus List. The stock has gained 31.53% since its April 2024 IPO at $69.15, now trading at $90.95. Six analysts raised earnings estimates in the last 60 days, with consensus estimates increasing $0.55 to $7.13 for fiscal 2026. The company is expected to deliver 16.7% earnings growth for the current fiscal year and has demonstrated a 13.2% average earnings surprise.

The iShares Semiconductor ETF (SOXX) receives a Zacks ETF Rank of 1 (Strong Buy) due to its low expense ratio of 0.33%, strong year-to-date performance of 66.3%, and broad exposure to the semiconductor sector. However, the ETF carries high risk with a beta of 1.80 and standard deviation of 38.8%, with concentrated exposure through top holdings like Nvidia (8.77%), Micron Technology, and Advanced Micro Devices.

YieldMax® announced monthly distributions for three Target 12™ ETFs on September 1, 2026. BIGY, RNTY, and SOXY each maintain a 12% target annual income level with distributions per share of $0.5265, $0.4879, and $0.8828 respectively. The announcement includes risk disclosures noting that distributions are variable and may be zero, with no guarantee of future performance.

Disc Medicine announced it will present clinical data from multiple programs at the SOHO 2026 Annual Meeting in Houston, including initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera patients and efficacy data from the RALLY-MF trial of DISC-0974 for myelofibrosis-associated anemia. The oral presentations are scheduled for September 9-12, 2026.

SoFi Technologies is transitioning from an online lender to a broad digital financial-services platform, with 51% of new products opened by existing members in Q2 (up from 35% YoY). The company's adjusted net revenues rose 40% YoY and adjusted EBITDA increased 44%, driven by cross-buy adoption and non-lending offerings now accounting for 87% of total products. However, SOFI stock has declined in 2026 despite operational progress, and current valuation assumes continued execution on its ecosystem strategy.

While Wall Street analysts show strong bullish sentiment on MINISO Group Holding Limited with an average brokerage recommendation of 1.50 (Strong Buy), the article cautions investors to rely more on Zacks Rank analysis. MINISO received a Zacks Rank #3 (Hold) rating due to unchanged earnings estimates of $1.56 for the current year, suggesting the stock may perform in line with the broader market rather than outperform.

HUTCHMED announced positive Phase III SANOVO trial results showing that ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) demonstrated statistically significant progression-free survival improvements and encouraging overall survival benefits in treatment-naïve patients with MET-overexpressing EGFR-mutated NSCLC in China, extending the clinical value of the combination into the first-line setting.